[Scabies therapy in Germany : Results of a nationwide survey with a special focus on the efficacy of first-line therapy with permethrin].

Skabiestherapie in Deutschland : Ergebnisse einer bundesweiten Umfrage mit besonderem Fokus auf die Wirksamkeit der Erstlinientherapie mit Permethrin.

Journal

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
ISSN: 1432-1173
Titre abrégé: Hautarzt
Pays: Germany
ID NLM: 0372755

Informations de publication

Date de publication:
May 2020
Historique:
pubmed: 8 3 2020
medline: 29 5 2020
entrez: 8 3 2020
Statut: ppublish

Résumé

According to the current scabies guideline, topical treatment with permethrin 5% cream is the first-line therapy of common scabies in Germany. However, in the course of growing incidence of scabies in recent years there have been increasing numbers of reports of reduced efficacy in standard therapy. To establish a better understanding for the efficacy of scabies therapy under practice conditions, a survey focusing on the first-line therapy with permethrin was conducted in dermatological hospitals, outpatient clinics and dermatology practices. The postal survey addressed all dermatologically active physicians in Germany and queried diagnostic methods, the individual initial treatment, the estimated efficacy of permethrin therapy, the frequency and reasons for therapy failures under permethrin and the therapeutic approach in case of failure of the initial therapy. The efficacy of permethrin was rated with 73% by 187 physicians. About 74% reported to treat initially with 5% permethrin cream. The most common reasons identified for treatment failure were application errors, lack of compliance and inadequate hygiene measures. Suspected diminished efficacy or development of resistance against permethrin and re-infestations were also mentioned. In the case of ineffectiveness of initial therapy, most clinicians opt for oral ivermectin, a repetition of permethrin therapy or a combination of both. Although there are localized reports of decreased effectiveness of permethrin therapy, results of this survey point towards a persisting high efficacy of first-line standard treatment of scabies with permethrin 5% cream in Germany.

Sections du résumé

BACKGROUND BACKGROUND
According to the current scabies guideline, topical treatment with permethrin 5% cream is the first-line therapy of common scabies in Germany. However, in the course of growing incidence of scabies in recent years there have been increasing numbers of reports of reduced efficacy in standard therapy.
OBJECTIVE OBJECTIVE
To establish a better understanding for the efficacy of scabies therapy under practice conditions, a survey focusing on the first-line therapy with permethrin was conducted in dermatological hospitals, outpatient clinics and dermatology practices.
METHODS METHODS
The postal survey addressed all dermatologically active physicians in Germany and queried diagnostic methods, the individual initial treatment, the estimated efficacy of permethrin therapy, the frequency and reasons for therapy failures under permethrin and the therapeutic approach in case of failure of the initial therapy.
RESULTS RESULTS
The efficacy of permethrin was rated with 73% by 187 physicians. About 74% reported to treat initially with 5% permethrin cream. The most common reasons identified for treatment failure were application errors, lack of compliance and inadequate hygiene measures. Suspected diminished efficacy or development of resistance against permethrin and re-infestations were also mentioned. In the case of ineffectiveness of initial therapy, most clinicians opt for oral ivermectin, a repetition of permethrin therapy or a combination of both.
CONCLUSION CONCLUSIONS
Although there are localized reports of decreased effectiveness of permethrin therapy, results of this survey point towards a persisting high efficacy of first-line standard treatment of scabies with permethrin 5% cream in Germany.

Identifiants

pubmed: 32144440
doi: 10.1007/s00105-020-04561-y
pii: 10.1007/s00105-020-04561-y
doi:

Substances chimiques

Antiparasitic Agents 0
Enzyme Inhibitors 0
Insecticides 0
Permethrin 509F88P9SZ

Types de publication

Journal Article

Langues

ger

Sous-ensembles de citation

IM

Pagination

374-379

Auteurs

B Hackenberg (B)

Hautarztpraxis Dr. Siebenhaar, Bergstr. 18-20, 42651, Solingen, Deutschland.

O N Horváth (ON)

Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität, Frauenlobstr. 9-11, 80337, München, Deutschland.

M Petachti (M)

Klinik für Dermatologie und Allergologie, Vivantes Klinikum Spandau, Neue Bergstr. 6, 13585, Berlin, Deutschland.

R Schult (R)

Hautarztpraxis Dr. Brinkmann, Schult & Samimi-Fard, Barbarastr. 15, 45964, Gladbeck, Deutschland.

N Yenigün (N)

Hautarztpraxis N. Yenigün, Sophienblatt 13-17, 24103, Kiel, Deutschland.

P Bannenberg (P)

InfectoPharm Arzneimittel und Consilium GmbH, Von-Humboldt-Str. 1, 64646, Heppenheim, Deutschland. paul.bannenberg@infectopharm.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH